<DOC>
	<DOCNO>NCT01083160</DOCNO>
	<brief_summary>This prospective , single-arm , post marketing observational study adult patient active rheumatoid arthritis ( RA ) discontinue treatment due lack efficacy , intolerance incomplete response either infliximab etanercept . The aim post-marketing observational study obtain data clinical outcome , compliance tolerability determine effectiveness switch infliximab etanercept adalimumab . In cohort , different treatment strategy study context routine clinical practice different participate place .</brief_summary>
	<brief_title>Clinical Outcomes , Compliance Effectiveness Switching From Infliximab Etanercept Adalimumab Patients With Active Rheumatoid Arthritis ( RA ) . A Multicenter Post-Marketing Observational Study Routine Clinical Use</brief_title>
	<detailed_description>This prospective , single-arm , post marketing observational study adult patient active RA discontinuing treatment due lack efficacy , intolerance incomplete response either infliximab etanercept . The aim post-marketing observational study obtain data clinical outcome , compliance tolerability determine effectiveness switch infliximab etanercept Adalimumab . In cohort , different treatment strategy study context routine clinical practice different participate place . Study Objectives : Primary objective : To assess effectiveness treatment adalimumab patient rheumatoid arthritis ( RA ) fail presented incomplete response current treatment either infliximab etanercept . Secondary objective : To evaluate compliance clinical tolerability adalimumab Investigational Plan Selection Study Population : All patient belong centre participate study meet inclusion criterion none exclusion criterion consider eligible . Patients consider eligible study give consent use and/or disclose patient 's personal and/or health data . Patient 's consent obtain his/her participation study document Informed Consent Form approve Ethics Committee .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Patients ≥18 &lt; 75 year age meet American College Rheumatology ( ACR ) criterion RA . Patients active RA define : 1 . ≥3 tender joint ≥3 swollen joint , 2 . DAS 28 score &gt; 3.1 Patients discontinue treatment either infliximab etanercept due : 1 . Lack efficacy , 2 . Incomplete response . Patients , opinion physician could result beneficiate locally approve treatment scheme adalimumab Those patient switch infliximab etanercept adalimumab do last 60 day could include study . The following patient include study : Patients active infection . Patients latent TB . For protocol , evidence latent TB infection define induration ( erythema ) 5 mm great , 4872 hr placement . Any suggested data clinical history chest xray . Patients participate another study clinical trial Any condition accord criterion participate physician represent obstacle study conduct and/or represent potential unacceptable risk patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Anti-TNF</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Infliximab</keyword>
	<keyword>Etanercept</keyword>
</DOC>